Announcements Trials
Browse Landscape

Phase

Phase 2 116Phase 3 58Phase 1 51Phase 1/2 38Phase 2/3 4Phase NA 3Phase EARLY_PHASE1 2Phase 4 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Lymphoma 2Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1

Interventions

Cyclophosphamide 21fludarabine 12Rituximab 10Vincristine 6Etoposide 6Prednisone 5Doxorubicin 5pembrolizumab 4Radiotherapy 4Methotrexate 4Magnetic Resonance Spectroscopy 4Immunotherapy, Adoptive 4Granulocyte Colony-Stimulating Factor 4Filgrastim 4Dexamethasone 4venetoclax 3ibrutinib 3Nivolumab 3Imiquimod 3Ifosfamide 3Exercise 3Biopsy 368Ga-pentixafor 3fludarabine phosphate 2daratumumab 2Transplantation 2Stem Cell Transplantation 2Specimen Handling 2Sirolimus 2Roflumilast 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Bendamustine Hydrochloride × Lymphoid × Clear all
NCT03295240 2025-05-13

The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma

Memorial Sloan Kettering Cancer Center

Phase EARLY_PHASE1 Completed
10 enrolled
Lymphoid

Lymphoma, Lymphoma, Mantle-Cell

NCT01022021 2017-01-10

Peripheral Blood Stem Cell (PBSC) Mobilization in Patients With Relapsed Lymphoma Treated With Bendamustine

University of Kansas Medical Center

Phase EARLY_PHASE1 Completed
17 enrolled
Lymphoid

Lymphoma, Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡